GlassScriptPhysician profile
Ryan Sung-Eun Cho
NPI 1699096180
$6,942.47
in general payments reported to CMS, 2019-2025
30 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2021: $281 · 2022: $310 · 2023: $1,736 · 2024: $1,865 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,377 · Travel and Lodging: $493 · Education: $27.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,377.28 |
| Travel and Lodging | $492.58 |
| Education | $27.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,423.82 | 2019-2024 | Spyglass, Exalt Model D, Captivator II |
| Abbvie INC. | $1,082.96 | 2022-2025 | Rinvoq, Mavyret, Skyrizi |
| Janssen Biotech, INC. | $568.11 | 2023-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $440.71 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $342.89 | 2022-2025 | |
| Celgene Corporation | $322.58 | 2023-2024 | Zeposia |
| Genzyme Corporation | $312.86 | 2023-2025 | |
| Madrigal Pharmaceuticals | $261.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $214.99 | 2022-2024 | Intellis Adaptivestim, Gi Genius |
| Lilly USA, LLC | $211.02 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $201.35 | 2023-2025 | Dupixent |
| Axonics, INC. | $195.31 | 2022 | |
| Organon LLC | $161.46 | 2023-2025 | Renflexis, Hadlima |
| Olympus America INC. | $149.94 | 2021 | |
| Qol Medical, LLC | $144.50 | 2024 | Sucraid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $122.79 | 2023-2024 | Entyvio, Eohilia |
| Celltrion USA INC. | $119.20 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $118.42 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $105.00 | 2023 | Vibativ |
| Fresenius Kabi USA, LLC | $93.79 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $87.53 | 2023-2025 | Zenpep |
| Ardelyx, INC. | $63.66 | 2025 | Ibsrela |
| Astellas Pharma US INC | $59.40 | 2023-2024 | Vyloy |
| Merck Sharp & Dohme LLC | $32.63 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $31.20 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $23.46 | 2022 | |
| Enterra Medical, INC. | $22.79 | 2024 | |
| Nestle Healthcare Nutrition INC. | $20.87 | 2023 | |
| Endogastric Solutions, INC | $8.21 | 2023 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.